US Broker Ratings

Royalty Pharma (RPRX) Stock Analysis: A Strategic Look at Growth and Valuation Potential

Royalty Pharma plc (NASDAQ: RPRX) presents a compelling opportunity for investors seeking exposure to the healthcare sector, particularly in the biotechnology industry. This company, headquartered in New York, operates as..

Lantheus Holdings, Inc. (LNTH) Stock Analysis: A 4.44% Potential Upside in the Healthcare Sector

Lantheus Holdings, Inc. (NASDAQ: LNTH) remains a compelling player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. With a market capitalization of $6.88 billion, this..

Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a biopharmaceutical company with a focus on RNA-targeted therapeutics and gene therapy, presents an intriguing prospect for investors navigating the dynamic biotech sector. With a..

Johnson & Johnson (JNJ)

⚠️ No article content returned.

..

Avantor, Inc. (AVTR) Stock Analysis: Navigating a Flat Revenue Growth Landscape with Strategic Insights

Avantor, Inc. (AVTR) stands as a noteworthy player in the healthcare sector, specifically in the medical instruments and supplies industry. With a market capitalization of $7.09 billion, the company provides..

Nuvalent, Inc. (NUVL) Investor Outlook: Navigating the Biotech Frontier with Groundbreaking Cancer Therapies

Nuvalent, Inc. (NASDAQ: NUVL) is carving a niche in the biotechnology sector with its innovative approach to cancer treatment. As a clinical-stage biopharmaceutical company, Nuvalent is committed to developing therapies..

iRhythm Holdings, Inc. (IRTC): Investor Outlook Reveals 53% Potential Upside Amid Strong Buy Ratings

iRhythm Holdings, Inc. (NASDAQ: IRTC) stands at the forefront of innovation in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $3.82 billion, this U.S.-based..

ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking the 93.83% Potential Upside

ADMA Biologics Inc (NASDAQ: ADMA) is making waves in the biotechnology sector with its promising outlook and robust financial metrics. Headquartered in Ramsey, New Jersey, ADMA Biologics develops and markets..

Natera, Inc. (NTRA) Stock Analysis: Revenue Growth Shines Amidst Challenging Valuation Metrics

Natera, Inc. (NASDAQ: NTRA) continues to capture the attention of investors with its remarkable revenue growth, despite facing challenging valuation metrics. As a key player in the healthcare sector, specifically..

Moderna, Inc. (MRNA) Stock Analysis: Navigating a Challenging Market with a -29.85% Potential Downside

The biotechnology sector is known for its volatility and rapid innovation, and Moderna, Inc. (NASDAQ: MRNA) is no exception. With a market cap of $27.09 billion, the company has been..

Insmed Incorporated (INSM): Investor Outlook on Potential 70.44% Upside in the Biotech Sector

Insmed Incorporated (NASDAQ: INSM) stands out in the biotechnology sector with a compelling growth narrative. As a leader in developing therapies for serious and rare diseases, the company is capturing..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 28.83% Potential Upside in the Healthcare Sector

AstraZeneca PLC (AZN), a prominent player in the healthcare sector, is capturing investor attention with a tantalizing potential upside of 28.83%. With its robust market capitalization of $266.15 billion, AstraZeneca..

Repligen Corporation (RGEN) Investor Outlook: Strong Buy Ratings and 22.75% Potential Upside

Repligen Corporation (NASDAQ: RGEN) continues to capture the attention of investors with its promising growth trajectory and robust product offerings in the healthcare sector. Specializing in bioprocessing technologies and systems,..

Smith & Nephew SNATS, Inc. (SNN): Investor Outlook on a Healthcare Giant with 10.98% Upside Potential

Smith & Nephew SNATS, Inc. (NYSE: SNN), a stalwart in the healthcare sector, is making waves in the medical devices industry. Headquartered in Watford, UK, this company has a rich..

Corcept Therapeutics (CORT) Stock Analysis: Evaluating the Biotech’s Growth Potential Amidst a Market Cap of $9.86 Billion

Corcept Therapeutics Incorporated (NASDAQ: CORT), a biopharmaceutical powerhouse, stands out in the dynamic biotechnology industry with a market capitalization of $9.86 billion. Headquartered in Redwood City, California, Corcept is renowned..

Inspire Medical Systems, Inc. (INSP) Stock Analysis: Navigating Potential Amidst Robust Revenue Growth in the Medical Device Sector

Inspire Medical Systems, Inc. (NASDAQ: INSP) presents a compelling narrative for investors interested in the healthcare sector, particularly in the rapidly evolving field of medical devices. With a focus on..

Teva Pharmaceutical Industries (TEVA): Exploring a 24% Upside Potential Amid Strong Buy Ratings

For investors keeping a keen eye on the healthcare sector, Teva Pharmaceutical Industries Limited (NYSE: TEVA) presents an intriguing opportunity. With a market capitalization of $38.37 billion, Teva stands as..

Option Care Health, Inc. (OPCH) Stock Analysis: Evaluating a 32.51% Upside Potential

Option Care Health, Inc. (NASDAQ: OPCH) has positioned itself as a significant player in the U.S. healthcare sector, specializing in home and alternate site infusion services. With a market capitalization..

Penumbra, Inc. (PEN) Stock Analysis: Exploring Growth Potential and Analyst Ratings in the Medical Device Sector

Penumbra, Inc. (NYSE: PEN), a prominent player in the healthcare sector, is capturing investors’ attention with its innovative medical devices and solid market positioning. Incorporated in 2004 and headquartered in..

ICON plc (ICLR) Stock Analysis: A Healthcare Giant with 7.81% Potential Upside

ICON plc (NASDAQ: ICLR), a leading player in the Healthcare sector specializing in Diagnostics & Research, is gaining attention from investors with its potential upside of 7.81%. Headquartered in Dublin,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds